<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926900</url>
  </required_header>
  <id_info>
    <org_study_id>SFB636 D6 2006-007090-72</org_study_id>
    <nct_id>NCT00926900</nct_id>
  </id_info>
  <brief_title>The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes</brief_title>
  <acronym>SFB636D6</acronym>
  <official_title>The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to explore whether the extinction of cue-reactivity following a
      cue-exposure based intervention in volunteers with an alcohol dependence is facilitated by
      drugs that increase NMDA-receptor function.

      It is hypothesised that targeted treatment with D-Cycloserine prior to each extinction
      training session enhances the effects on cue-reactivity.

      Further, a significant correlation between the reduction of cue-reactivity and both reduced
      craving and relapse probability is expected.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in cue-reactivity to alcohol-associated stimuli assessed by functional magnetic resonance imaging</measure>
    <time_frame>following completion of cue-exposure therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to first severe relapse to alcohol consumption</measure>
    <time_frame>at 3 and 6 months after treatment completion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Alcohol Drinking</condition>
  <arm_group>
    <arm_group_label>D-cycloserine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-cycloserine</intervention_name>
    <description>50 mg at approximately 1.5 hours prior to cue-exposure training sessions</description>
    <arm_group_label>D-cycloserine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  current DSM-IV/ ICD-10 diagnosis of alcohol dependence

          -  controlled abstinence for a period of 5 to 21 days following admission to inpatient
             detoxification or day-clinic care

          -  women (in childbearing age): use of a highly effective method of contraception

          -  normal or corrected-to-normal vision

          -  ability to provide written informed consent

        Exclusion Criteria:

          -  diagnosis of additional axis I or II disorders (according to DSM-IV( ICD- 10 criteria)
             either currently or within the past 12 months (except nicotine dependence)

          -  positive drug screening

          -  current medication with anti-convulsive or psychotropic drugs

          -  MRI ineligibility

          -  sensitivity to study medication as evidenced by a history of adverse drug experience

          -  severe withdrawal symptoms (e.g. convulsions, delirium)

          -  disposition towards experiencing convulsions/ epilepsy

          -  history of schizophrenic disorders/ affective psychosis

          -  neurological diseases that might affect the dopaminergic, limbic and frontal cortices
             or extrapyramidal motor functioning

          -  major diseases (e.g. diabetes, liver cirrhosis, heart disease)

          -  physical illness interfering with study procedures or affecting study outcomes

          -  pregnancy (positive test results)/ lactation period

          -  suicidal tendencies/ increased risk that others might be harmed -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Falk Kiefer, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Institute of Mental Health, Department of Addictive Behavior and Addiction Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Falk Kiefer, Professor</last_name>
    <phone>+49 621 1703 3522</phone>
    <email>falk.kiefer@zi-mannheim.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central Institute of Mental Health</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Falk Kiefer, Professor</last_name>
      <phone>+49 621 1703 3522</phone>
      <email>falk.kiefer@zi-mannheim.de</email>
    </contact>
    <investigator>
      <last_name>Falk Kiefer, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.zi-mannheim.de/start_en.html</url>
    <description>website of the Central Institute of Mental Health</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2009</study_first_submitted>
  <study_first_submitted_qc>June 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2009</study_first_posted>
  <last_update_submitted>November 24, 2011</last_update_submitted>
  <last_update_submitted_qc>November 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcoholism</keyword>
  <keyword>D-cycloserine</keyword>
  <keyword>extinction</keyword>
  <keyword>cue-exposure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 28, 2013</submitted>
    <returned>April 9, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

